ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $121.98 million versus the consensus estimate of $124.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.